Important Phase 1 study for Zapnometinib published
In close collaboration with fellow scientists, ACliRA Consulting ApS participated in the publication of an important Phase 1 study for the compound Zapnometinib, a MEK-inhibitor with excellent immunmodulating properties in development for the treatment of viral respiratory infections. The company…

